C R Gibbs1, A D Blann, R D Watson, G Y Lip. 1. Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.
Abstract
BACKGROUND: To investigate the hypothesis that abnormalities of hemorheological (fibrinogen, plasma viscosity), endothelial (von Willebrand factor [vWF]), and platelet (soluble P-selectin) function would exist in patients with chronic heart failure (CHF) who are in sinus rhythm, we conducted a cross-sectional study of 120 patients with stable CHF (median ejection fraction 30%). We also hypothesized that ACE inhibitors and beta-blockers would beneficially affect the measured indices. METHODS AND RESULTS: In the cross-sectional analysis, plasma viscosity (P=0.001), fibrinogen (P=0.02), vWF (P<0.0001), and soluble P-selectin (P<0.001) levels were elevated in patients with CHF compared with healthy controls. Women demonstrated greater abnormalities of hemorheological indices and vWF than males (all P<0.05). Plasma viscosity (P=0.009) and fibrinogen (P=0.0014) levels were higher in patients with more severe symptoms (New York Heart Association [NYHA] class III-IV), but there was no relationship with left ventricular ejection fraction. When ACE inhibitors were introduced, there was a reduction in fibrinogen (repeated-measures ANOVA, P=0.016) and vWF (P=0.006) levels compared with baseline. There were no significant changes in hemorheological, endothelial, or platelet markers after the introduction of beta-blocker therapy, apart from a rise in mean platelet count (P<0.001). CONCLUSIONS: Abnormal levels of soluble P-selectin, vWF, and hemorheological indices may contribute to a hypercoagulable state in CHF, especially in female patients and in those with more severe NYHA class. Treatment with ACE inhibitors improved the prothrombotic state in CHF, whereas the addition of beta-blockers did not. These positive effects of ACE inhibitors may offer an explanation for the observed reduction in ischemic events in clinical trials.
BACKGROUND: To investigate the hypothesis that abnormalities of hemorheological (fibrinogen, plasma viscosity), endothelial (von Willebrand factor [vWF]), and platelet (soluble P-selectin) function would exist in patients with chronic heart failure (CHF) who are in sinus rhythm, we conducted a cross-sectional study of 120 patients with stable CHF (median ejection fraction 30%). We also hypothesized that ACE inhibitors and beta-blockers would beneficially affect the measured indices. METHODS AND RESULTS: In the cross-sectional analysis, plasma viscosity (P=0.001), fibrinogen (P=0.02), vWF (P<0.0001), and soluble P-selectin (P<0.001) levels were elevated in patients with CHF compared with healthy controls. Women demonstrated greater abnormalities of hemorheological indices and vWF than males (all P<0.05). Plasma viscosity (P=0.009) and fibrinogen (P=0.0014) levels were higher in patients with more severe symptoms (New York Heart Association [NYHA] class III-IV), but there was no relationship with left ventricular ejection fraction. When ACE inhibitors were introduced, there was a reduction in fibrinogen (repeated-measures ANOVA, P=0.016) and vWF (P=0.006) levels compared with baseline. There were no significant changes in hemorheological, endothelial, or platelet markers after the introduction of beta-blocker therapy, apart from a rise in mean platelet count (P<0.001). CONCLUSIONS: Abnormal levels of soluble P-selectin, vWF, and hemorheological indices may contribute to a hypercoagulable state in CHF, especially in female patients and in those with more severe NYHA class. Treatment with ACE inhibitors improved the prothrombotic state in CHF, whereas the addition of beta-blockers did not. These positive effects of ACE inhibitors may offer an explanation for the observed reduction in ischemic events in clinical trials.
Authors: Marjan Mujib; Abu-Ahmed Z Rahman; Ravi V Desai; Mustafa I Ahmed; Margaret A Feller; Inmaculada Aban; Thomas E Love; Michel White; Prakash Deedwania; Wilbert S Aronow; Gregg Fonarow; Ali Ahmed Journal: Am J Cardiol Date: 2010-12-22 Impact factor: 2.778
Authors: Christopher S Lee; Jill M Gelow; Quin E Denfeld; James O Mudd; Donna Burgess; Jennifer K Green; Shirin O Hiatt; Corrine Y Jurgens Journal: J Cardiovasc Nurs Date: 2014-07 Impact factor: 2.083
Authors: Amy I Lynch; Eric Boerwinkle; Barry R Davis; Charles E Ford; John H Eckfeldt; Catherine Leiendecker-Foster; Donna K Arnett Journal: Pharmacogenet Genomics Date: 2009-06 Impact factor: 2.089
Authors: Patrick M Pullicino; John L P Thompson; Ralph L Sacco; Alexandra R Sanford; Min Qian; John R Teerlink; Haissam Haddad; Monika Diek; Ronald S Freudenberger; Arthur J Labovitz; Marco R Di Tullio; Dirk J Lok; Piotr Ponikowski; Stefan D Anker; Susan Graham; Douglas L Mann; J P Mohr; Shunichi Homma Journal: Cerebrovasc Dis Date: 2013-07-30 Impact factor: 2.762